06/04/2017
Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor
First-in-human trial of novel inhibitor targeting accumulation of toxic neurofibrillary tau tangles to fight neurodegenerative diseases including dementia [...]
